eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | multiple endocrine neoplasia type 1 |
| Comorbidity | C0007131|nsclc |
| Sentences | 3 |
| PubMedID- 20071052 | Rc could be an active second-line regimen in patients with relapsed nsclc who responded to first-line chemotherapy. |
| PubMedID- 24116196 | Despite the improvement made to chemotherapy in the last 2 decades, the current response rate to platinum-based regimen is about 19% in patients with advanced nsclc and the median survival is only 7–9 months. |
| PubMedID- 23741274 | [12] however, the optimal chemotherapy regimen in patients with stage iii nsclc is still controversial. |
Page: 1